Garheng Kong, M.D., Ph.D., Chairman – Founder and Managing Partner of HealthQuest Capital
Dr. Kong is currently the Founder and Managing Partner of HealthQuest Capital, which he founded in 2013 as a Managing Partner at Sofinnova Ventures. Dr. Kong joined Sofinnova Ventures in 2010 as a General Partner to focus on life science investments. A physician and engineer by training, Dr. Kong has 16 years of experience investing in innovative healthcare companies with a long list of successes. For the previous 10 years, he was at Intersouth Partners, most recently as a General Partner. During this time he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline) and lead investor of the first financing for Alimera Sciences (NASDAQ: ALIM). He has also led or been significantly involved with the investments of Cempra Pharmaceuticals (NASDAQ: CEMP, Chairman), Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation, TransEnterix, Calibra Medical (Acquired by Johnson & Johnson), CancerGuide Diagnostics, Aldagen (Acquired by Cytomedix) and nContact Surgical. Dr. Kong currently serves on the boards of portfolio companies including Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, and Histogenics (HSGX).
Dr. Kong has also served or is serving on the boards of directors of Southeast BIO, the North Carolina Biotechnology Center, the Duke University Medical Center Board of Visitors, the Council for Entrepreneurial Development (CED), the Hamner Institutes for Life Sciences, the North Carolina Medical Device Organization, the University of Florida Biotechnology Council, the University of Virginia Ivy Foundation, the Pennsylvania Life Sciences Greenhouse, the Southeast Universities Research Association, the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research and the Corporate Chaplains of America. He has also served on the Duke Medical Center Institutional Review Board (IRB) and on the faculty at the Duke Fuqua School of Business as a Senior Scholar. Dr. Kong received his M.D. (Medical Scientist Training Program), Ph.D. in biomedical engineering and M.B.A. from Duke University, graduating at the top of both his medical and business school classes. He also holds B.S. degrees in chemical engineering and biological sciences from Stanford University.
Josh Baltzell, Venture Partner at Sightline Partners and Venture Partner – Split Rock Partners
Mr. Baltzell is a Venture Partner at SightLine Partners, and also serves as a Venture Partner at Split Rock Partners, LLC. He has been with Split Rock Partners since 2004 and with SightLine since 2014. Mr. Baltzell has more than 20 years of experience in the healthcare industry. Prior to his tenure in the venture capital industry, Mr. Baltzell held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector, as well as various marketing and business development positions with SCIMED and Boston Scientific. Mr. Baltzell currently serves on the boards of Colorescience, EBR Systems, Inc., Entellus Medical (NASDAQ: ENTL), DFINE, Inc., and RF Surgical Systems, Inc. Mr. Baltzell holds a B.A. in economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.
David Gill, Chairman, Audit Committee
Mr. Gill served as Chief Financial Officer of EndoChoice Holdings, Inc. (NYSE: GI), a publicly traded medical device company from August 2014 to November 2016, and as President and Chief Operating Officer from March 2016 to November 2016. He served as the Chief Financial Officer of INC Research Holdings Inc. (NASDAQ: INCR), a clinical research organization, from February 2011 to August 2013, and served as a board member and audit committee chairman of INC Research from 2007 to 2010. From March 2009 to February 2011, Mr. Gill was the Chief Financial Officer of TransEnterix (NYSEMKT: TRXC), a then private medical device company. From July 2005 to November 2006, Mr. Gill was Chief Financial Officer and Treasurer of NxStage Medical, Inc. (NASDAQ: NXTM), a publicly traded dialysis equipment company. He currently serves as a Director of Melinta Therapeutics (NASDAQ: MLNT), an antibiotics company. From 2006 to 2011, he served on several public and private company boards of directors, including those of LeMaitre Vascular (NASDAQ: LMAT), a publicly traded medical device company, and IsoTis, Inc., a publicly traded orthobiologics company that was acquired by Integra LifeSciences Holdings Corporation in October 2007. From January 2002 to May 2005, Mr. Gill served as Senior Vice President and Chief Financial Officer of CTI Molecular Imaging, Inc., a publicly traded medical imaging company, until its sale to Siemens AG. Mr. Gill has led initial public offerings for four companies and has raised more than $600 million in equity and $600 million in debt over his career. Mr. Gill holds a B.S. degree, cum laude, in accountancy from Wake Forest University and an M.B.A. degree, with honors, from Emory University.
John Johnson, Independent Member
Mr. Johnson has served as a member of the Board since November 2013. Mr. Johnson served as President and Chief Executive Officer of Dendreon Corporation from January 2012 to August 2014. Mr. Johnson previously served as the Chief Executive Officer and a Director of Savient Pharmaceuticals, Inc., a pharmaceutical company, from January 2011 until January 2012, and prior to that time, served as Senior Vice President and President of Eli Lilly and Company’s oncology unit from November 2009 until January 2011. He was also Chief Executive Officer of ImClone Systems Incorporated from 2007 until November 2009, and served on ImClone’s board of directors until it was acquired by Eli Lilly in 2008. Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit from 2005 until 2007, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 until 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 until 2003. Mr. Johnson currently serves as Chairman of the Board of Directors of Strongbridge Biopharma plc, and as a director of Aveo Oncology, Melinta Therapeutics, Inc. (f/k/a Cempra, Inc.), Portola Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, Inc. He also served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and as a member of the Health Section Governing Board of Biotechnology Industry Organization. He graduated with a B.S. from the East Stroudsburg University of Pennsylvania.
Michael Lewis, Chairman of Oceana Investment Partners LLP
Mr. Lewis has more than 25 years of experience in the investment management and retail industries. He is current Chairman of Oceana investment Corporation Limited, a private U.K. investment company, and is also a Partner of Oceana Investment Partners LLP, a U.K. investment advisor. Mr. Lewis is Chairman of Strandbags Holdings Pty Limited, an Australian retail company comprising some 450 stores and a Non-Executive Director of The Foschini Group Limited, a South African retail company with some 2,000 stores.
Mr. Lewis serves on the Board of United Trust Bank Limited, a U.K.-based bank, and served on the Supervisory Board of Axel Springer AG in Germany from April 2007 to September 2012. He previously worked for Ivory and Sime, a money manager based in Scotland, and Lombard Odier, a money manager based in England. He has an undergraduate degree in political science and economics and a postgraduate degree in economics from the University of Cape Town, South Africa.
Adam Gridley, President and Chief Executive Officer – Histogenics
Mr. Gridley has more than 20 years of experience in the medical device, biotechnology and pharmaceutical industries. Before joining Histogenics, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquisition by Merz. Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a B.S. and a M.B.A. from the University of Denver.
Kevin Rakin, Independent Member
Mr. Rakin has more than 20 years of experience in the biotechnology industry and was most recently the President of Regenerative Medicine at Shire plc, a leading specialty biopharmaceutical company (Shire). Prior to joining Shire, Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from 2007 until its acquisition by Shire for $750 million in June 2011. Before this, he served as the interim CEO of ABH and executive-in-residence at Canaan Partners. Previously, he was a co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, a publicly-held pharmacogenomics company, until its merger with Clinical Data in October 2005. Prior to that, he was Genaissance’s President and Chief Financial Officer and was responsible for completing private and public financings in excess of $150 million.
Mr. Rakin currently serves on a number of boards including Oramed Pharmaceuticals, Inc., Aziyo Biologics, Inc., Cheetah Medical Inc. and Tela Bio, Inc. He has previously served as a board member for Ipsogen SA, Vion Pharmaceuticals, OMRIX Biopharmaceuticals and Clinical Data. He holds an M.B.A. from Columbia University and received his graduate and undergraduate degrees in commerce from the University of Cape Town, South Africa.
Susan Washer, President and Chief Executive Officer, Applied Genetic Technologies Corporation
Ms. Washer is the President and Chief Executive Officer of AGTC, where she has served in such capacity since March 2002 and as a member of its board of directors since November 2003. Ms. Washer was also AGTC’s Chief Operating Officer from October 2001 to March 2002. From June 1994 to October 2001, Ms. Washer led two entrepreneurial firms including serving as President and CEO of Scenic Productions and as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing STEM based technology from Florida universities. Ms. Washer currently serves on the board of directors of Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Previously, Ms. Washer served as chairman of the BioFlorida board and the Southeast BIO board and continues her involvement with both organizations as a member of their respective boards.
From October 1983 to June 1994, Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida.